ONAPRISTONE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H39NO3
Molecular Weight	449.6249
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C1=CC=C(C=C1)[C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]4CCC5=CC(=O)CCC5=C24

InChI

InChIKey=IEXUMDBQLIVNHZ-YOUGDJEHSA-N

InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C29H39NO3
Molecular Weight	449.6249
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30304013 | https://adisinsight.springer.com/drugs/800000877 | https://clinicaltrials.gov/ct2/show/NCT03909152

Onapristone is a type I progesterone receptor (PR) antagonist that prevents PR- mediated DNA transcription and was studied as an antitumor agent. This drug possessed activity in breast cancer and is participating in phase II clinical trials to test any good and bad effect for the treatment of endometrial cancer, ovarian cancer, peritoneal cancer, and prostate cancer.

Approval Year

PubMed

Title	Date	PubMed
Luteoprotective roles of luteinizing hormone are mediated by not only progesterone production but also glucocorticoid conversion in bovine corpus luteum.	2013-03	23325624
Anti-apoptotic roles of prostaglandin E2 and F2alpha in bovine luteal steroidogenic cells.	2008-08	18463360
Regulation of homeobox A10 expression in the primate endometrium by progesterone and embryonic stimuli.	2007-09	17709569
Progesterone-induced sphingosine kinase-1 expression in the rat uterus during pregnancy and signaling consequences.	2007-04	17164439
Effects of progesterone on iNOS, COX-2, and collagen expression in the cervix.	2006-06	16399999
Ligand-selective targeting of the glucocorticoid receptor to nuclear subdomains is associated with decreased receptor mobility.	2005-06	15705660
Characterization of a critical region in the hormone binding domain of sperm progesterone receptor.	2005-04	15811074
Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.	2003-06-16	12781198
Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.	1996-04-26	8627601

Patents

Sample Use Guides

In Vivo Use Guide

onapristone tablets 10, 20, 30, 40 or 50 mg BID

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:20:32 GMT 2025` Edited by `admin` on `Mon Mar 31 19:20:32 GMT 2025`
Record UNII	H6H7G23O3N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ONAPRISTONE

Official Name

English

ZK-299

Preferred Name

English

ZK299

Code

English

onapristone [INN]

Common Name

English

11.BETA.-(P-(DIMETHYLAMINO)PHENYL)-17.ALPHA.-HYDROXY-17-(3-HYDROXYPROPYL)-13.ALPHA.-ESTRA-4,9-DIEN-3-ONE

Common Name

English

ZK98299

Code

English

ZK-98299

Code

English

ONAPRISTONE [MI]

Common Name

English

Onapristone [WHO-DD]

Common Name

English

Code System Code Type Description

CAS

96346-61-1